Research by Manisha Samy, ARK Analyst

  • Stem Cell Banner

    The Stem Cell Revolution

    by | Health
    Mentioned Companies: BAYRY, BIIB, CRSP, EDIT, GSK, NTLA, NVS

    Discovered nearly thirty years ago in 1988[1], stem cell technology has failed to transform the field of regenerative medicine…until no­­w. After delivering only one treatment during three decades of development, stem cell technology could finally become the all-purpose tool for repairing the body, thanks to rapid and precise genome editing techniques such as CRISPR and […]

  • alzheimer's treatment

    Alzheimer’s: Solving a Major Unmet Need

    by | Health
    Mentioned Companies: ACIU, AVXL, BIIB

    An Alzheimer’s treatment that converts the neurodegenerative disease from a cruel killer into a tolerable chronic condition could become the best selling drug in history.1 According to ARK’s estimates, the annual revenue associated with an effective Alzheimer’s treatment could approximate to $120 billion USD.2 While many companies have attempted to develop an effective treatment, not one has […]

  • CRISPR Gene Editing

    The CRISPR Gene Editing Approach to Treating and Curing Diseases

    by | Health

    The Promise DNA (Deoxyribonucleic acid) is the “source code” of life, and now we can edit and correct that code efficiently and cost-effectively should there be a disease-causing error. In other words, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)[1] gene editing could save millions of lives and cure thousands of genetic disorders, if it is to […]

  • health care innovation, drug approval, Companion Diagnostics, cdx, ark research,

    Companion Diagnostics (CDx): More Drugs At A Fraction Of The Cost

    by | Health
    Mentioned Companies: ABBV, AZN, FMI, ILMN, MYGN, NSTG, NVTA

    Prime Time for Companion Diagnostics We think the drug approval process remains convoluted, costly, and time-consuming, but it is about to change. The increased adoption of Companion Diagnostics (CDx)—tests that identify the most suitable patients for a particular treatment—holds much promise. ARK expects that CDx will improve patient outcomes demonstrably, reduce research and development spending […]

  • Zika Virus, Zika Virus research

    Will Cerus INTERCEPT Prevent the Transmission of the Zika Virus?

    by | Health
    Mentioned Companies: CERS, INO, NLNK, XON

    Amid a global epidemic, the Food and Drug Administration (FDA) has issued new guidelines for blood banks to prevent the contamination and transmission of the Zika virus. While whole blood donations are banned in Zika-endemic parts of the world, Cerus INTERCEPT would enable the safe collection and transfusion of plasma and platelets. Two years after […]